Key result
CaSM-Seq8 chimeric VLPs induce higher and longer-lasting anti-FMDV IgG levels in mice vs commercial vaccines.
Why the study?
Utilizing virus-like particles as vaccine carriers to present exogenous antigens is promising and challenging, motivating investigation into the potential of Hepatitis E virus truncated capsid protein as a carrier.
Does the CaSM-Seq8 chimeric VLP vaccine improve anti-FMDV IgG levels compared to Seq8 alone or commercial vaccine in BALB/c mice?
Does the CaSM-Seq8 chimeric VLP vaccine improve anti-FMDV IgG levels compared to Seq8 alone or commercial vaccine in BALB/c mice?
The HEV truncated capsid protein can serve as an effective VLP carrier for exogenous antigens, significantly enhancing the immunogenicity and stability of a chimeric foot-and-mouth disease vaccine candidate in mice.
Does not support veterinary translation; leaves open HEV-based chimeric VLPs as FMDV antigen carriers in target species.
Background: Virus like particle (VLP), a multiprotein structure which is assembled automatically, can stimulate robust immune responses due to an appropriate size, repetitive epitopes, and a structure similar to native virions. Utilizing VLPs as vaccine carriers to present exogenous antigens is a promising and challenging field in vaccine design. Hence, this study aims to investigate the potential of Hepatitis E virus (HEV) truncated capsid protein as a VLP carrier presenting foreign antigens in vaccine design.Results: S and M domains of HEV ORF2 protein (aa112-455) were selected as an optimal carrier (CaSM). The exogenous antigen Seq8 containing three immunogenic domains from three different foot-and-mouth disease virus (FMDV) strains was linked to the C-terminal of CaSM to construct a chimeric VLP vaccine candidate (CaSM-Seq8). Morphological analysis showed that CaSM-Seq8 self-assembled into VLPs with a diameter of approximately 26 nm, similar to the VLPs of CaSM alone but smaller than native HEV virions. Further, the thermal stability and the proteolysis resistance of Seq8 were enhanced when carried by CaSM. The antigenicity analysis revealed a more robust reactivity against anti-FMDV specific antibodies when Seq8 was presented on the CaSM particles. Upon injection into mice, anti-FMDV IgGs induced by CaSM-Seq8 appeared earlier, increased faster, and maintained higher levels for a longer time than those induced by Seq8 antigen alone or a commercial inactivated FMDV vaccine.Conclusions: This study demonstrates the potential of the HEV truncated capsid protein VLPs as a presenting-platform of exogenous antigens in vaccine design and promising preliminary results on chimeric VLP vaccine against foot-and-mouth disease.
No takes yet. Share an insight, caveat, or question.
LU et al. (2019) studied Foot-and-mouth disease (vaccine development) (n=40). CaSM-Seq8 (chimeric VLP vaccine) vs. Seq8 alone, commercial FMDV inactivated vaccine, or Saline was evaluated on Anti-FMDV IgG levels. CaSM-Seq8 chimeric VLPs induced higher, earlier, and longer-lasting anti-FMDV IgG levels in mice compared to Seq8 antigen alone or a commercial inactivated FMDV vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: